These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10051112)

  • 1. Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans.
    Kegeles LS; Zea-Ponce Y; Abi-Dargham A; Rodenhiser J; Wang T; Weiss R; Van Heertum RL; Mann JJ; Laruelle M
    Synapse; 1999 Mar; 31(4):302-8. PubMed ID: 10051112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.
    Abi-Dargham A; van de Giessen E; Slifstein M; Kegeles LS; Laruelle M
    Biol Psychiatry; 2009 Jun; 65(12):1091-3. PubMed ID: 19167701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.
    Abi-Dargham A; Kegeles LS; Zea-Ponce Y; Mawlawi O; Martinez D; Mitropoulou V; O'Flynn K; Koenigsberg HW; Van Heertum R; Cooper T; Laruelle M; Siever LJ
    Biol Psychiatry; 2004 May; 55(10):1001-6. PubMed ID: 15121484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPECT imaging of striatal dopamine release after amphetamine challenge.
    Laruelle M; Abi-Dargham A; van Dyck CH; Rosenblatt W; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Charney DS; Hoffer PB; Kung HF
    J Nucl Med; 1995 Jul; 36(7):1182-90. PubMed ID: 7790942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.
    Laruelle M; Iyer RN; al-Tikriti MS; Zea-Ponce Y; Malison R; Zoghbi SS; Baldwin RM; Kung HF; Charney DS; Hoffer PB; Innis RB; Bradberry CW
    Synapse; 1997 Jan; 25(1):1-14. PubMed ID: 8987142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.
    Catafau AM; Bullich S; Danús M; Penengo MM; Cot A; Abanades S; Farré M; Pavía J; Ros D
    Synapse; 2008 Jan; 62(1):62-9. PubMed ID: 17960766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: a comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride.
    Narendran R; Frankle WG; Mason NS; Rabiner EA; Gunn RN; Searle GE; Vora S; Litschge M; Kendro S; Cooper TB; Mathis CA; Laruelle M
    Synapse; 2009 Jun; 63(6):447-61. PubMed ID: 19217025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography.
    Booij J; Korn P; Linszen DH; van Royen EA
    Eur J Nucl Med; 1997 Jun; 24(6):674-7. PubMed ID: 9169577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study.
    Pogarell O; Koch W; Pöpperl G; Tatsch K; Jakob F; Zwanzger P; Mulert C; Rupprecht R; Möller HJ; Hegerl U; Padberg F
    J Psychiatr Res; 2006 Jun; 40(4):307-14. PubMed ID: 16259998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms.
    Pogarell O; Koch W; Karch S; Dehning S; Müller N; Tatsch K; Poepperl G; Möller HJ
    Pharmacopsychiatry; 2012 May; 45 Suppl 1():S36-41. PubMed ID: 22565233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB; Malison RT; al-Tikriti M; Hoffer PB; Sybirska EH; Seibyl JP; Zoghbi SS; Baldwin RM; Laruelle M; Smith EO
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters.
    Seibyl JP; Laruelle M; van Dyck CH; Wallace E; Baldwin RM; Zoghbi S; Zea-Ponce Y; Neumeyer JL; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Feb; 37(2):222-8. PubMed ID: 8667048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients.
    Anand A; Verhoeff P; Seneca N; Zoghbi SS; Seibyl JP; Charney DS; Innis RB
    Am J Psychiatry; 2000 Jul; 157(7):1108-14. PubMed ID: 10873919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine.
    Castner SA; al-Tikriti MS; Baldwin RM; Seibyl JP; Innis RB; Goldman-Rakic PS
    Neuropsychopharmacology; 2000 Jan; 22(1):4-13. PubMed ID: 10633485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride.
    Narendran R; Hwang DR; Slifstein M; Talbot PS; Erritzoe D; Huang Y; Cooper TB; Martinez D; Kegeles LS; Abi-Dargham A; Laruelle M
    Synapse; 2004 Jun; 52(3):188-208. PubMed ID: 15065219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.
    Laruelle M
    J Cereb Blood Flow Metab; 2000 Mar; 20(3):423-51. PubMed ID: 10724107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.